XERS
Xeris Biopharma Holdings, Inc.
+0.10 (+1.29%)7.88USD693K成交股數1.4B市值–本益比(近四季)4.3股價營收比+28.7%營收年增(近四季)2026-11-05下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 92.1M+53% | 83.1M+38% | 74.4M+37% | 71.5M+49% | 60.1M+48% | 60.1M+24% | 54.3M+43% | 48.1M+45% | 40.6M | 48.3M | 38.0M | 33.2M |
| 營業成本 | 12.5M | 10.6M | 11.0M | 11.9M | 8.7M | 9.5M | 13.6M | 7.8M | 6.0M | 8.2M | 7.6M | 5.3M |
| 毛利 | 79.6M+55% | 72.6M+43% | 63.4M+56% | 59.6M+48% | 51.4M+48% | 50.6M+26% | 40.7M+34% | 40.3M+44% | 34.7M | 40.1M | 30.5M | 27.9M |
| 毛利率 | 86.4% | 87.3% | 85.2% | 83.4% | 85.5% | 84.2% | 75.0% | 83.8% | 85.3% | 83.0% | 80.1% | 84.0% |
| 研發費用 | 10.7M | 8.8M | 7.5M | 8.1M | 7.8M | 6.1M | 5.9M | 5.8M | 7.8M | 5.0M | 6.1M | 4.8M |
| 銷售管理費用 | 61.0M | 53.1M | 46.5M | 44.4M | 44.0M | 40.1M | 45.0M | 40.0M | 38.4M | 37.3M | 37.6M | 33.6M |
| 營業利益 | 5.2M-267% | 7.9M+371% | 6.7M-152% | 4.5M-155% | −3.1M-78% | 1.7M-134% | −12.9M-19% | −8.2M-38% | −14.2M | −4.9M | −16.0M | −13.3M |
| 營業利益率 | 5.6% | 9.5% | 9.0% | 6.3% | -5.1% | 2.8% | -23.8% | -17.0% | -35.1% | -10.2% | -42.0% | -40.0% |
| 稅後淨利 | −31.1M+237% | 2.2M-144% | 621K-104% | −1.9M-87% | −9.2M-51% | −5.1M-58% | −15.7M-21% | −15.0M-11% | −19.0M | −12.2M | −19.8M | −16.8M |
| 淨利率 | -33.8% | 2.7% | 0.8% | -2.7% | -15.3% | -8.5% | -29.0% | -31.2% | -46.7% | -25.2% | -52.2% | -50.7% |
| 稀釋 EPS | -0.18+200% | 0.01-150% | 0.00-100% | -0.01-90% | -0.06-57% | -0.02-78% | -0.11-21% | -0.10-17% | -0.14 | -0.09 | -0.14 | -0.12 |
| 稀釋股數 | 173M | 178M | 178M | 159M | 152M | 147M | 149M | 148M | 141M | 138M | 137M | 137M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 122M | 112M | 91.6M | 59.3M | 58.4M | 71.6M | 59.2M | 57.6M | 62.7M | 46.1M | 46.2M | 51.0M |
| 應收帳款 | 58.1M | 56.3M | 53.8M | 53.0M | 46.3M | 40.4M | 41.1M | 42.4M | 37.4M | 46.0M | 30.2M | 30.9M |
| 存貨 | 80.9M | 74.2M | 67.5M | 67.3M | 52.7M | 48.2M | 45.1M | 43.0M | 40.9M | 38.1M | 36.5M | 29.0M |
| 總資產 | 412M | 392M | 370M | 335M | 315M | 323M | 321M | 332M | 337M | 328M | 329M | 321M |
| 有息負債 | 189M | 221M | 219M | 219M | 218M | 217M | 216M | 230M | 230M | 190M | 188M | 188M |
| 總負債 | 422M | 379M | 371M | 354M | 351M | 353M | 349M | 351M | 346M | 324M | 315M | 291M |
| 股東權益 | −9.7M | 13.0M | −861K | −19.3M | −35.1M | −29.6M | −28.3M | −19.3M | −9.2M | 3.9M | 13.6M | 30.0M |
| 負債比 | 102.4% | 96.7% | 100.2% | 105.8% | 111.1% | 109.2% | 108.8% | 105.8% | 102.7% | 98.8% | 95.9% | 90.6% |
| 淨現金(現金 − 有息負債) | −67.1M | −109M | −128M | −159M | −159M | −145M | −157M | −173M | −167M | −144M | −142M | −137M |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 9.9M | – | – | −10.0M-51% | – | – | – | −20.3M | – | – | −26.1M |
| 資本支出 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流 | – | – | – | – | – | – | – | – | – | – | – | – |
| 折舊攤銷 | – | 337K | – | – | 315K | – | – | – | 326K | – | – | 364K |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | – | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
產品／服務2025 年度 · 292M
| Recorlev | 139M | 47.7% | +116.7% |
|---|---|---|---|
| Gvoke | 94.1M | 32.2% | +13.6% |
| Keveyis | 47.6M | 16.3% | -3.8% |
| Royalty Contract And Other Revenue | 8.8M | 3.0% | +37.4% |
| Product Other | 2.0M | 0.7% | – |
| 產品 小計 | 283M | 97.0% | +43.9% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 292M | +43.7% | 554K | 0.2% | 0.00 | – |
| FY2024 | 203M | +23.9% | −54.8M | -27.0% | -0.37 | – |
| FY2023 | 164M | +48.7% | −62.3M | -38.0% | -0.45 | – |
| FY2022 | 110M | +122.3% | −94.7M | -85.9% | -0.70 | – |
| FY2021 | 49.6M | +146.0% | −123M | -247.5% | -1.55 | −96.6M |
| FY2020 | 20.2M | – | −91.1M | -452.2% | -2.14 | −80.9M |